# **Shareholder Update**

December 2019

Amplia Therapeutics Limited ASX: ATX



#### **Notice**



The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited ("ATX") in any jurisdiction. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.


This presentation contains forward-looking statements which can be identified by the use of words such as "may", "should", "will", "expect", "anticipate", "believe", "estimate", "intend", "scheduled" or "continue" or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to ATX, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of ATX's acquired product pipeline. Actual results from clinical trials may vary from those shown.

#### **Investment Highlights**




- ATX's technology addresses a multi-\$Bn market opportunity:
  - Unmet clinical need in pancreatic and ovarian cancer
  - Impact in chronic fibrotic diseases: hepatic, pulmonary
- Experienced team with a stellar record in drug development and partnering
- 2019 was pivotal in terms of advancement toward the clinic and commercial execution



## Multiple 'shots on goal' for ATX's pipeline






## **2019: Accomplishments**



ATX has established the foundation for clinical development of its FAK assets

- Modest capital raise
- ✓ GMP<sup>1</sup> drug manufacture at kilogram scale
- Safety studies in two species to support clinical translation with clear evidence of safety
- Clinical trial design and establishment of relationships with Key Opinion Leaders (KOLs)
- Efficacy studies that demonstrate ATX's molecules are highly differentiated / competitive
- Further meaningful protection of our intellectual property through new IP capture and extension of patent life out to late 2032



<sup>1</sup> Good Manufacturing Practice.

## **Toward Clinical Studies**

THE RAPEUTICS

During 2019, ATX established collaborations with clinical KOLs in Australia and Internationally

- Multiple opportunities for innovative and costeffective clinical trials of ATX's FAK inhibitors in both cancer patients and healthy volunteers to support a range of indications
- Rapid pathway to Phase II studies internationally in key cancer indications (pancreatic and ovarian cancer)



#### **Drug Manufacturing and Intellectual Property**

Amplia has filed new international patents to protect the optimal formulation of the lead candidate (AMP945)

- The optimised form of AMP945 has now been manufactured at kg scale by a reputable contract manufacturer
- Suitable for clinical use, plenty of material to support planned clinical studies, oral use (once daily)
- Has been on a stability program for 9 months (bulk drug stability)
- Has remained stable, retained requisite pharmaceutical potency





# **Safety Profiling of AMP945**

AMP945 has been tested in preclinical safety studies in two species


- These studies provide a valuable preliminary view of AMP945's toxicology
  - ✓ Enable confident dose selection
- The aims of these studies were met
  - No unexpected findings were made in preliminary studies
  - ✓ Dose ranges have been selected for further toxicology studies to support both healthy volunteer studies and US IND requirements





#### ATX's Lead Program (AMP945) is Differentiated

- Non-selective kinase inhibitors may exhibit more clinical side-effects / toxicity
  - ✓ We already know that AMP945 is a highly selective inhibitor of FAK
  - ✓ AMP945 has a very 'clean' kinome profile
- We have now run a study to directly compare AMP945's selectivity to that of our closest competitor, defactinib (Verastem)
  - ✓ As expected, AMP945 was shown to be much more selective for FAK than defactinib
  - ✓ Fewer off-target effects
  - Likely to be better tolerated in patients than defactinib



AMP945 is a more selective inhibitor than defactinib



## **2020 Corporate Objectives**



- Initiation of the first clinical trials of AMP945
- Further pre-clinical development to support the clinical evaluation of AMP886
- Pharma business development activity around ATX's core assets
- Completion of IND-enabling studies that, subject to regulatory approvals, will support a rapid Phase II oncology combination therapy





For further information please contact

John Lambert PhD Chief Executive Officer

> john@ampliatx.com www.ampliatx.com